Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (141)	10/19/1999 3:30:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 438

(1) Issue of Science paper already clear. Context of Rick's post, I thought, was gene therapy. Thus my confusion. BTW, there is another key GZMO Science paper, this one pretty "old", 1993 or so, and that is the one describing SAGE. Actually, they may be two SAGE papers in Science. None of those had GZMO people as authors, but they are certainly GZMO relevant. (2) Thanks for the "non-biological" analysis. Very good points all. The only issue (see RW Reeves' posts on this) is the possible limitation on upside given the GENZ connection. So, yes GENZ will not willingly let its children fail, but if it looks like one of them is going to be very successful, GENZ has the right, and duty to its own shareholders, to take it out at a relatively small premium. But, see and argue with Reeves on this. I am just summarizing his arguments. After all, the advantages you list come at a price, so to speak. (3) As for the Harvard MBA, I'd say I take a MS in Chem E from Wash U any day (someone named Mark Levin, for example) -g- PB